2005
DOI: 10.1200/jco.2005.07.120
|View full text |Cite
|
Sign up to set email alerts
|

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Abstract: Cetuximab and cisplatin is an active regimen in refractory SCCHN. The relative contribution of cetuximab is better defined in a single-agent trial. Cetuximab did not exacerbate cisplatin toxicity but was associated with skin rash in a majority of patients and occasional serious allergic reactions. Further study of this compound is warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
177
1
8

Year Published

2007
2007
2015
2015

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 377 publications
(193 citation statements)
references
References 27 publications
5
177
1
8
Order By: Relevance
“…This analysis compared data from 3 prospective Phase II studies with cetuximab in patients with recurrent and/or metastatic SCCHN who progressed on platinum-based therapy, 27,28,30 all of which followed an open, multicenter design, with data from a retrospective study of various second-line treatments in a similar group of patients. 6,7 The 3 prospective studies were designed to investigate the efficacy and safety of either cetuximab monotherapy or cetuximab in combination with cisplatin or carboplatin.…”
Section: Study Designsmentioning
confidence: 99%
See 4 more Smart Citations
“…This analysis compared data from 3 prospective Phase II studies with cetuximab in patients with recurrent and/or metastatic SCCHN who progressed on platinum-based therapy, 27,28,30 all of which followed an open, multicenter design, with data from a retrospective study of various second-line treatments in a similar group of patients. 6,7 The 3 prospective studies were designed to investigate the efficacy and safety of either cetuximab monotherapy or cetuximab in combination with cisplatin or carboplatin.…”
Section: Study Designsmentioning
confidence: 99%
“…30,31 Patients received a minimum of 2 cycles 28,29 or 4 cycles 30,31 of therapy, at which point all patients with at least stable disease (SD) continued either until they developed PD or until the occurrence of unacceptable side effects with either the same combination regimen 28,29 or with cetuximab alone. 30,31 In the retrospective study, 68 patients (45%) patients received BSC, 43 patients (28%) received chemotherapy, 25 patients (17%) received radiotherapy, and 15 patients (10%) received chemoradiotherapy. In total, therefore, 58 patients received secondline chemotherapy either alone (n 5 43) or in combination with radiotherapy (n 5 15).…”
Section: Treatments Administeredmentioning
confidence: 99%
See 3 more Smart Citations